Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy

Barbara Stam; Erik van der Bijl; Judi van Diessen; Maddalena M G Rossi; Angela Tijhuis; José S A Belderbos; Eugène Damen; Jan-Jakob Sonke

doi:10.1016/j.radonc.2017.09.004

Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy

Radiother Oncol. 2017 Oct;125(1):62-65. doi: 10.1016/j.radonc.2017.09.004. Epub 2017 Sep 19.

Authors

Barbara Stam¹, Erik van der Bijl¹, Judi van Diessen¹, Maddalena M G Rossi¹, Angela Tijhuis¹, José S A Belderbos¹, Eugène Damen¹, Jan-Jakob Sonke²

Affiliations

¹ Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: [email protected].

PMID: 28939179
DOI: 10.1016/j.radonc.2017.09.004

Abstract

Association of heart dose and overall survival was investigated in a cohort including 469 locally-advanced NSCLC patients receiving daily low-dose hypofractionated chemo-radiotherapy. Significant associations were found over a range of dose parameters. Multivariate analysis showed significant associations of heart_V_2Gy:HR=1.007%^-1 (95% CI:1.002-1.013; p=0.006), age:HR=1.026year^-1 (1.011-1.042; p=0.001) and GTV volume:HR=1.001cc^-1 (1.000-1.002; p=0.006) with overall survival.

Keywords: Chemoradiation; Heart toxicity; Locally advanced non-small cell lung cancer.

MeSH terms

Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / radiotherapy*
Chemoradiotherapy* / adverse effects
Cohort Studies
Female
Heart / radiation effects*
Humans
Lung Neoplasms / mortality
Lung Neoplasms / radiotherapy*
Male
Middle Aged
Radiation Dose Hypofractionation*